depression on semaglutide is associated with a 44% decreased risk of and a 38% decreased risk of anxiety GLP-1 drugs linked to less

Explore the benefits, risks and expectations.

A 90-day self-assessment form lets weight loss patients sell themselves on the next program

CagriSema is a fixed-dose combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist), and is currently an experimental obesity drug developed by Novo Nordisk

Kelly Clarkson revealed that she was diagnosed with prediabetes, a condition characterized by higher-than-normal blood sugar levels, during an episode of her talk show.

2020;12(3):859

Learn about FDA-approved injection sites, proper technique for the lateral abdominal area, site rotation strategies, and safety considerations for this once-weekly medication.